AinosAIMD
AIMD
About: Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
Employees: 46
0
Funds holding %
of 6,794 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
0.94% more ownership
Funds ownership: 1.34% [Q2] → 2.28% (+0.94%) [Q3]
0% more funds holding
Funds holding: 9 [Q2] → 9 (+0) [Q3]
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
7% less capital invested
Capital invested by funds: $71.3K [Q2] → $66.4K (-$4.9K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for AIMD.
Financial journalist opinion
Based on 5 articles about AIMD published over the past 30 days
Neutral
Accesswire
3 days ago
Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing
SAN DIEGO, CA / ACCESSWIRE / December 4, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research has issued a report highlighting Ainos' strategic partnership with Taiwan Tanabe Seiyaku for manufacturing and marketing VELDONA®, a novel therapeutic candidate for primary Sjögren's syndrome, in Taiwan. The report underscores the significance of Ainos' efforts to out-license VELDONA®, starting with this key regional partnership, and sets the stage for future global expansion.
Neutral
Newsfile Corp
5 days ago
Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug
San Diego, California--(Newsfile Corp. - December 2, 2024) - Ainos, Inc. (NASDAQ: AIMD) (NASDAQ: AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today proudly announced the signing of a strategically significant Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation in Japan, brings extensive pharmaceutical development and manufacturing expertise to the partnership.
Neutral
Accesswire
3 weeks ago
Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments
Taiwan regulatory approval for the trial expected in Q1 2025 Remains committed to a capital-efficient business strategy SAN DIEGO, CA / ACCESSWIRE / November 13, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report on the Company's obtainment of Institutional Review Board ("IRB") approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the VELDONA® clinical study for primary Sjogren's syndrome, along with 3Q24 results and multiple other developments. The report said an approval from Taiwan's Food and Drug Administration (TFDA) for the study is expected in next quarter, with the trial set to start around April 2025 and completion in December 2026.
Neutral
Accesswire
3 weeks ago
Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025
IRB approval on track as scheduled Next step is obtaining all regulatory approvals, followed by site initiation visit VELDONA significantly increases unstimulated whole salivary flow in prior Phase 3 studies SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has received Institutional Review Board ("IRB") approval from Shuang Ho Hospital, affiliated with Taipei Medical University (IRB Approval No.: TMU-JIRB No.
Neutral
Accesswire
4 weeks ago
Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities
SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-powered point-of-care testing (POCT) and low-dose interferon therapeutics, today announced it has filed complaints with NASDAQ MarketWatch and the U.S. Securities and Exchange Commission (SEC), due to concerns about unusual trading activity in its common stock, specifically large-volume sell orders. Ainos suspects that these trading activities may involve regulatory violations and urges the regulators to investigate thoroughly to uphold market fairness and protect stockholder interests.
Neutral
Accesswire
1 month ago
Ainos Reports Third Quarter 2024 Financial Results
Secured multi-regional patent assets, strengthening Ainos' AI Nose technology. Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.
Neutral
Accesswire
1 month ago
Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets
Strengthens AI Nose Gas Sensing Technology with Additional Exclusively Licensed Patents Secures Exclusive Rights to Breakthrough Nitrogen-Oxygen Separation Technology with Superior Energy Efficiency and Ultra-Low Carbon Emissions, Advancing Sustainable Medical Practices SAN DIEGO, CA / ACCESSWIRE / October 28, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it has secured exclusive licensing rights for an additional 28 multi-regional patent assets from its strategic shareholder and product co-developer, Taiwan Carbon Nano Technology Corporation ("TCNT"). These patents encompass innovations in AI Nose gas sensing technology and extend Ainos' technological capabilities with a groundbreaking nitrogen-oxygen separation technology targeting medical applications.
Neutral
Accesswire
1 month ago
Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast
Prioritizing VELDONA®'s development for oral warts in HIV+ patients and Sjogren's syndrome Burgeoning pet care market also presents growth opportunities for VELDONA® SAN DIEGO, CA / ACCESSWIRE / October 24, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, shared promising clinical progress of VELDONA® and its growth opportunities alongside upcoming milestones in the Water Tower Research ("WTR") Small-Cap Spotlight podcast, signaling strong potential for both human and animal health markets. WTR has published a report recapping highlights from the podcast.
Neutral
Accesswire
2 months ago
Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies
Ainos pioneers AI-powered digital nose technology with VOC detection breakthroughs for early disease diagnosis, industrial safety, and human-like sensory capabilities in robots VELDONA® low-dose oral interferon technology demonstrates huge potential in in viral, autoimmune, and veterinary treatments SAN DIEGO, CA / ACCESSWIRE / October 7, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced that it continues to push the boundaries of global smart healthcare and immunotherapy innovation. With its AI Nose and VELDONA® low-dose oral interferon technologies, Ainos is not only spearheading advancements in medical technology but also demonstrating significant potential for industrial safety and automation applications.
Neutral
Accesswire
2 months ago
Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA
Next step will be receiving approval from Taiwan Food and Drug Administration (TFDA) SAN DIEGO, CA / ACCESSWIRE / September 25, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced it has received Institutional Review Board (IRB) approval from the National Taiwan University Hospital for its clinical trial focused on treating oral warts in HIV-positive patients. This trial will evaluate VELDONA®, Ainos' low-dose oral interferon formulation, which has received orphan drug designation from the U.S. Food and Drug Administration ("FDA"), as a potential treatment for HIV-related oral warts.
Charts implemented using Lightweight Charts™